TGFB3 and neoplasm: As a result, SHC1-OE-ASM treated with TGFB3 showed significantly elevated tumor cell migration rates, whereas OE-Ctrl-ASM showed no significantly changes in tumor cell migration rates after treated with TGFB3 (Fig. 2F).